RBC Capital analyst Brian Abrahams said Biogen (NASDAQ: BIIB) investors may be disappointed that the company was not at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE